• KAFM
  • Contact us
  • E-Submission
ABOUT
ARTICLE CATEGORY
BROWSE ARTICLES
AUTHOR INFORMATION

Page Path

1
results for

"Yoon-Jong Bae"

Filter

Article category

Keywords

Publication year

"Yoon-Jong Bae"

Original Article
Background
In addition to its antidiabetic effects, metformin has pleiotropic effects, such as the inhibition of carcinogenesis. This study aimed to investigate the association between metformin use and pancreatic cancer risk in the Korean National Health Insurance Service (NHIS)-National Health Screening Cohort (HEALS).
Methods
Of the individuals in the Korean NHIS-HEALS, 29,271 men and 19,091 women were included in the final analysis after propensity score matching based on age, body mass index, and smoking status. The study population was categorized into three groups: metformin non-users with diabetes mellitus (DM), metformin users with DM, and non-diabetic users. A Cox proportional hazards regression model was used to examine the association between metformin use and pancreatic cancer.
Results
The median follow-up period was 12.9 years. The estimated pancreatic cancer incidence was highest in metformin users with DM, regardless of sex (P<0.001), and lowest in non-diabetic men and female metformin non-users (P=0.053). The hazard ratios (95% confidence interval) for pancreatic cancer incidence in metformin users and non-diabetic individuals were 1.116 (0.648–1.923) and 0.447 (0.259–0.771) in men and 2.769 (1.003–7.642) and 1.451 (0.529–3.984) in women, respectively, after full adjustment.
Conclusion
Women with diabetes using metformin are at a higher risk of pancreatic cancer than women with diabetes not using metformin. Meanwhile, men with DM using metformin have a similar risk of pancreatic cancer as men with DM not using metformin.

Citations

Citations to this article as recorded by  
  • Rising Pancreatic Adenocarcinoma and Type 2 Diabetes Mellitus-Related Mortality in the United States, 2000 to 2024, With Forecasts to 2034
    Arkadeep Dhali, Rick Maity, Abdul R. Faisal, Muhammad U. Saeed, Ali Shan Hafeez, Asad Zaman, Jyotirmoy Biswas, Adnan Bhat
    American Journal of Clinical Oncology.2026;[Epub]     CrossRef
  • Preventive and Therapeutic effects of Metformin in Cancer: A Meta- Analysis of RCT and Cohort Studies
    Mikiyas Amare Getu, Xianbin Zhang, Jia Wang, Kunpeng Xu, Ying Ying, Li Ma, Peng Gong
    Current Cancer Drug Targets.2026; 26(3): 379.     CrossRef
  • Long-Term Association Between GLP-1 Receptor Agonist Use and Incident Pancreatic Cancer: A Propensity Score–Matched Retrospective Cohort Study Using the TriNetX Network
    Muhammad Ali Ibrahim Kazi, Junaid Khan, Syed Musa Mufarrih, Maham Siddiqui, Huzaifa Ul Haque Ansari, Muhammad Ahmed, Imran Qureshi, Abdulhameed Al-Sabban, Nihaal Prashant Karnik, Andrew Gilman, Sanmeet Singh, Andrew Canakis
    Journal of Gastrointestinal Cancer.2026;[Epub]     CrossRef
  • Metformin: A Dual-Role Player in Cancer Treatment and Prevention: A Comprehensive Systematic Review and Meta-Analysis
    Imran Rangraze, Adil Farooq Wali, Mohamed El-Tanani, Mohamed Anas Patni, Syed Arman Rabbani, Rasha Babiker, Shakta Mani Satyam, Yahia El-Tanani, Manfredi Rizzo
    Medicina.2025; 61(6): 1021.     CrossRef
  • Unusual Manifestations of Primary Pancreatic Neoplasia
    Emilia Włoszek, Kamila Krupa, Marta Fudalej, Hanna Miski, Anna M. Badowska-Kozakiewicz, Andrzej Deptała
    Cancers.2025; 17(19): 3240.     CrossRef
  • A survey of the use of EHR as real-world evidence for discovering and validating new drug indications
    Nabasmita Talukdar, Xiaodan Zhang, Shreya Paithankar, Hui Wang, Bin Chen
    Drug Discovery Today.2025; 30(12): 104552.     CrossRef
  • Metformin adverse event profile: a pharmacovigilance study based on the FDA Adverse Event Reporting System (FAERS) from 2004 to 2022
    Yikuan Du, Jinfeng Zhu, Zhuoming Guo, Zhenjie Wang, Yuni Wang, Mianda Hu, Lingzhi Zhang, Yurong Yang, Jinjin Wang, Yixing Huang, Peiying Huang, Mianhai Chen, Bo Chen, Chun Yang
    Expert Review of Clinical Pharmacology.2024; 17(2): 189.     CrossRef
  • Metformin: A Dual-Role Player in Cancer Treatment and Prevention
    Mariam Ahmed Galal, Mohammed Al-Rimawi, Abdurrahman Hajeer, Huda Dahman, Samhar Alouch, Ahmad Aljada
    International Journal of Molecular Sciences.2024; 25(7): 4083.     CrossRef
  • Anti-Diabetic Therapies and Cancer: From Bench to Bedside
    Dimitris Kounatidis, Natalia G. Vallianou, Irene Karampela, Eleni Rebelos, Marina Kouveletsou, Vasileios Dalopoulos, Petros Koufopoulos, Evanthia Diakoumopoulou, Nikolaos Tentolouris, Maria Dalamaga
    Biomolecules.2024; 14(11): 1479.     CrossRef
  • Exploring the Basic Molecular Pathways: Metformin as a Potential Treatment Option for Pancreatic Cancer
    Sepehr Ramezani, Dariush Moslemi, Faezeh Firuzpour, Hamidreza Didar, Seyedamirmohammad Mazloumi, Narjes rezaeiroushan
    Iranian Journal of Blood and Cancer.2024; 16(4): 56.     CrossRef
  • Diabetes Mellitus in Pancreatic Cancer: A Distinct Approach to Older Subjects with New-Onset Diabetes Mellitus
    Jan Bures, Darina Kohoutova, Jan Skrha, Bohus Bunganic, Ondrej Ngo, Stepan Suchanek, Pavel Skrha, Miroslav Zavoral
    Cancers.2023; 15(14): 3669.     CrossRef
  • 7,940 View
  • 101 Download
  • 9 Web of Science
  • 11 Crossref
TOP